Key Documents

View All Documentation

27715

L-(+)-Lactic acid

Name: <SC>L</SC>-(+)-Lactic acid
Brand: SIAL

80%, liquid

Synonym(s):

(S)-2-Hydroxypropionic acid, Sarcolactic acid

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₃H₆O₃

CAS Number:

79-33-4

Molecular Weight:

90.08

NACRES:

NA.21

PubChem Substance ID:

57648269

UNSPSC Code:

12352100

MDL number:

MFCD00064266

Beilstein/REAXYS Number:

1720251

Assay:

80%

Form:

liquid

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Product Name

L-(+)-Lactic acid, 80%

Quality Level

100

assay

80%

form

liquid

ign. residue

≤0.1% (as SO₄)

solubility

water: soluble(lit.)

anion traces

chloride (Cl^-): ≤50 mg/kg, sulfate (SO₄^2-): ≤100 mg/kg

cation traces

Ca: ≤100 mg/kg, Fe: ≤10 mg/kg

antibiotic activity spectrum

Gram-negative bacteria

mode of action

cell membrane | interferes

SMILES string

C[C@H](O)C(O)=O

InChI

1S/C3H6O3/c1-2(4)3(5)6/h2,4H,1H3,(H,5,6)/t2-/m0/s1

InChI key

JVTAAEKCZFNVCJ-REOHCLBHSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Catalysts

Chiral Catalysts & Ligands

Acids for Laboratory, Analysis, and Regulated Applications

Application

Pharmaceutical and biomaterial applications: L-(+)-Lactic acid enhances M2 macrophage polarization through regulation of the PCK2/AMPK/mTOR signaling pathway in poly-L-lactic acid membranes, indicating its vital role in biomedicine and materials science (Tang et al., 2024).

Agricultural biotechnology: The induction of defense responses in tobacco against Phytophthora nicotianae by L-(+)-Lactic acid underscores its potential application in agricultural biotechnology for plant disease management (Yan et al., 2024).

Biochem/physiol Actions

Use as a substrate for the lactic acid dehydrogenase enzymes.

pictograms

GHS05

signalword

Danger

hcodes

H314

pcodes

P280 - P303 + P361 + P353 - P304 + P340 + P310 - P305 + P351 + P338 - P363 - P405

Hazard Classifications

Eye Dam. 1 - Skin Corr. 1

supp_hazards

EUH071

Storage Class

8A - Combustible corrosive hazardous materials

wgk

WGK 1

flash_point_f

230.0 °F

flash_point_c

110 °C

ppe

Faceshields, Gloves, Goggles, type ABEK (EN14387) respirator filter

Regulatory Information

涉药品监管产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Synthesis and characterization of pH-sensitive hydrogels based on chitosan and D, L-lactic acid.

Qu X, et al.

Journal of Applied Polymer Science, 74(13), 3193-3202 (1999)

Recovery of L-(+)-lactic acid by anion exchange resin Amberlite IRA-400.

Cao X, et al.

Biochemical Engineering Journal, 11(2), 189-196 (2002)

Metabolic origins of spatial organization in the tumor microenvironment.

Carlos Carmona-Fontaine et al.

Proceedings of the National Academy of Sciences of the United States of America, 114(11), 2934-2939 (2017-03-02)

The genetic and phenotypic diversity of cells within tumors is a major obstacle for cancer treatment. Because of the stochastic nature of genetic alterations, this intratumoral heterogeneity is often viewed as chaotic. Here we show that the altered metabolism of

Swelling and hydrolytic degradation of poly (D, L-lactic acid) in aqueous solutions.

Proikakis C S, et al.

Polymer Degradation and Stability, 91(3), 614-619 (2006)

A double-blind, randomized, placebo-controlled pilot study to investigate the effects of finasteride combined with a biodegradable self-reinforced poly L-lactic acid spiral stent in patients with urinary retention caused by bladder outlet obstruction from benign prostatic hyperplasia.

T Isotalo et al.

BJU international, 88(1), 30-34 (2001-07-12)

To assess whether patients in acute urinary retention from benign prostatic enlargement can be treated with a combined therapy comprising finasteride and a bioabsorbable self-reinforced poly L-lactic acid (SR-PLLA) urethral stent. Fifty-five patients in acute urinary retention were treated as

View All Related Papers

Global Trade Item Number

SKU	GTIN
27715-1L-R	04061826193266

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service